NO20054311L - HIV-repliksjonsinhiberende pyrimidiner og triaziner - Google Patents

HIV-repliksjonsinhiberende pyrimidiner og triaziner

Info

Publication number
NO20054311L
NO20054311L NO20054311A NO20054311A NO20054311L NO 20054311 L NO20054311 L NO 20054311L NO 20054311 A NO20054311 A NO 20054311A NO 20054311 A NO20054311 A NO 20054311A NO 20054311 L NO20054311 L NO 20054311L
Authority
NO
Norway
Prior art keywords
triazines
hiv replication
replication inhibitory
pyrimidines
inhibitory pyrimidines
Prior art date
Application number
NO20054311A
Other languages
English (en)
Other versions
NO20054311D0 (no
Inventor
Jan Heeres
Kurt Hertogs
Marc Rene De Jonge
Lucien Maria Henricus Koymans
Eva Bettens
Jerome Emile George Guillemont
Elisabeth Therese Jea Pasquier
Paulus Joannes Lewi
Frederik Frans Desire Daeyaert
Hendrik Maarten Vinkers
Original Assignee
Tibotec Pharm Ltd
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Tibotec Pharm Ltd filed Critical Tibotec Pharm Ltd
Publication of NO20054311D0 publication Critical patent/NO20054311D0/no
Publication of NO20054311L publication Critical patent/NO20054311L/no

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D239/00—Heterocyclic compounds containing 1,3-diazine or hydrogenated 1,3-diazine rings
    • C07D239/02—Heterocyclic compounds containing 1,3-diazine or hydrogenated 1,3-diazine rings not condensed with other rings
    • C07D239/24—Heterocyclic compounds containing 1,3-diazine or hydrogenated 1,3-diazine rings not condensed with other rings having three or more double bonds between ring members or between ring members and non-ring members
    • C07D239/28—Heterocyclic compounds containing 1,3-diazine or hydrogenated 1,3-diazine rings not condensed with other rings having three or more double bonds between ring members or between ring members and non-ring members with hetero atoms or with carbon atoms having three bonds to hetero atoms with at the most one bond to halogen, directly attached to ring carbon atoms
    • C07D239/46—Two or more oxygen, sulphur or nitrogen atoms
    • C07D239/47—One nitrogen atom and one oxygen or sulfur atom, e.g. cytosine
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
    • A61K31/505—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
    • A61K31/505—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim
    • A61K31/513—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim having oxo groups directly attached to the heterocyclic ring, e.g. cytosine
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/12—Antivirals
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/12—Antivirals
    • A61P31/14—Antivirals for RNA viruses
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/12—Antivirals
    • A61P31/14—Antivirals for RNA viruses
    • A61P31/18—Antivirals for RNA viruses for HIV
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D239/00—Heterocyclic compounds containing 1,3-diazine or hydrogenated 1,3-diazine rings
    • C07D239/02—Heterocyclic compounds containing 1,3-diazine or hydrogenated 1,3-diazine rings not condensed with other rings
    • C07D239/24—Heterocyclic compounds containing 1,3-diazine or hydrogenated 1,3-diazine rings not condensed with other rings having three or more double bonds between ring members or between ring members and non-ring members
    • C07D239/28—Heterocyclic compounds containing 1,3-diazine or hydrogenated 1,3-diazine rings not condensed with other rings having three or more double bonds between ring members or between ring members and non-ring members with hetero atoms or with carbon atoms having three bonds to hetero atoms with at the most one bond to halogen, directly attached to ring carbon atoms
    • C07D239/46—Two or more oxygen, sulphur or nitrogen atoms
    • C07D239/48—Two nitrogen atoms
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D405/00—Heterocyclic compounds containing both one or more hetero rings having oxygen atoms as the only ring hetero atoms, and one or more rings having nitrogen as the only ring hetero atom
    • C07D405/02—Heterocyclic compounds containing both one or more hetero rings having oxygen atoms as the only ring hetero atoms, and one or more rings having nitrogen as the only ring hetero atom containing two hetero rings
    • C07D405/12—Heterocyclic compounds containing both one or more hetero rings having oxygen atoms as the only ring hetero atoms, and one or more rings having nitrogen as the only ring hetero atom containing two hetero rings linked by a chain containing hetero atoms as chain links
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D413/00—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and oxygen atoms as the only ring hetero atoms
    • C07D413/02—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and oxygen atoms as the only ring hetero atoms containing two hetero rings
    • C07D413/12—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and oxygen atoms as the only ring hetero atoms containing two hetero rings linked by a chain containing hetero atoms as chain links

Landscapes

  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • General Health & Medical Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Animal Behavior & Ethology (AREA)
  • Pharmacology & Pharmacy (AREA)
  • General Chemical & Material Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Virology (AREA)
  • Communicable Diseases (AREA)
  • Oncology (AREA)
  • Molecular Biology (AREA)
  • Epidemiology (AREA)
  • Engineering & Computer Science (AREA)
  • AIDS & HIV (AREA)
  • Tropical Medicine & Parasitology (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Plural Heterocyclic Compounds (AREA)
  • Nitrogen Condensed Heterocyclic Rings (AREA)

Abstract

Denne oppfinnelse vedrører HTV-reproduksjonsinhibitorer med formel. N-oksidene, de farmasøytisk akseptable addisjonssalter, de kvaternære aminer og de stereokjemisk isomere former derav, deres anvendelse som medisin, fremgangsmåter ved deres fremstilling og farmasøytiske sammensetninger inneholdende dem.
NO20054311A 2003-02-20 2005-09-19 HIV-repliksjonsinhiberende pyrimidiner og triaziner NO20054311L (no)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
EP03100411 2003-02-20
US47501203P 2003-06-02 2003-06-02
PCT/EP2004/050175 WO2004074261A1 (en) 2003-02-20 2004-02-20 Hiv replication inhibiting pyrimidines and triazines

Publications (2)

Publication Number Publication Date
NO20054311D0 NO20054311D0 (no) 2005-09-19
NO20054311L true NO20054311L (no) 2005-10-27

Family

ID=32910137

Family Applications (2)

Application Number Title Priority Date Filing Date
NO20054312A NO20054312L (no) 2003-02-20 2005-09-19 HIV-replikasjonsinhiberende pyrimidiner og triaziner
NO20054311A NO20054311L (no) 2003-02-20 2005-09-19 HIV-repliksjonsinhiberende pyrimidiner og triaziner

Family Applications Before (1)

Application Number Title Priority Date Filing Date
NO20054312A NO20054312L (no) 2003-02-20 2005-09-19 HIV-replikasjonsinhiberende pyrimidiner og triaziner

Country Status (27)

Country Link
US (2) US7585870B2 (no)
EP (2) EP1597238B1 (no)
JP (2) JP4586013B2 (no)
KR (2) KR20050094896A (no)
CN (2) CN100572364C (no)
AP (1) AP2005003373A0 (no)
AR (2) AR044499A1 (no)
AT (2) ATE506353T1 (no)
AU (2) AU2004213187B2 (no)
BR (2) BRPI0407741B8 (no)
CA (2) CA2516699C (no)
CL (2) CL2004000303A1 (no)
CY (1) CY1106788T1 (no)
DE (2) DE602004006383T2 (no)
DK (1) DK1597238T3 (no)
EA (2) EA010423B1 (no)
ES (1) ES2287734T3 (no)
HR (2) HRP20050820A2 (no)
IL (2) IL169596A (no)
MX (2) MXPA05008867A (no)
MY (1) MY138308A (no)
NO (2) NO20054312L (no)
NZ (2) NZ542428A (no)
PL (2) PL226954B1 (no)
PT (1) PT1597238E (no)
TW (2) TW200500346A (no)
WO (2) WO2004074262A1 (no)

Families Citing this family (36)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
TWI329105B (en) 2002-02-01 2010-08-21 Rigel Pharmaceuticals Inc 2,4-pyrimidinediamine compounds and their uses
ES2445208T3 (es) 2002-07-29 2014-02-28 Rigel Pharmaceuticals, Inc. Compuestos de 2,4-pirimidindiamina para uso en métodos para tratar o prevenir enfermedades autoinmunitarias
CL2004000303A1 (es) * 2003-02-20 2005-04-08 Tibotec Pharm Ltd Compuestos derivados de pirimidinas y triazinas; proceso de preparacion; composicion farmaceutica; y su uso para inhibir la replicacion del vih.
BRPI0413018B8 (pt) 2003-07-30 2021-05-25 Rigel Pharmaceuticals Inc composto, e, uso de um composto
KR20070011458A (ko) 2004-04-08 2007-01-24 탈자진 인코포레이티드 키나제의 벤조트리아진 억제제
PL382308A1 (pl) 2004-08-25 2007-08-20 Targegen, Inc. Związki heterocykliczne i sposoby stosowania
EP1814878B1 (en) 2004-11-24 2012-01-04 Rigel Pharmaceuticals, Inc. Spiro-2, 4-pyrimidinediamine compounds and their uses
DE602006010979D1 (de) 2005-01-19 2010-01-21 Rigel Pharmaceuticals Inc Prodrugs aus 2,4-pyrimidindiamin-verbindungen und ihre verwendungen
US20070203161A1 (en) 2006-02-24 2007-08-30 Rigel Pharmaceuticals, Inc. Compositions and methods for inhibition of the jak pathway
WO2006133426A2 (en) 2005-06-08 2006-12-14 Rigel Pharmaceuticals, Inc. Compositions and methods for inhibition of the jak pathway
US8133900B2 (en) 2005-11-01 2012-03-13 Targegen, Inc. Use of bi-aryl meta-pyrimidine inhibitors of kinases
US8604042B2 (en) 2005-11-01 2013-12-10 Targegen, Inc. Bi-aryl meta-pyrimidine inhibitors of kinases
CN103626742B (zh) 2005-11-01 2017-04-26 塔格根公司 激酶的联-芳基间-嘧啶抑制剂
CA2642229C (en) 2006-02-24 2015-05-12 Rigel Pharmaceuticals, Inc. Compositions and methods for inhibition of the jak pathway
EP2114902B1 (en) * 2006-12-29 2014-09-17 Janssen R&D Ireland Hiv inhibiting 5,6-substituted pyrimidines
JP5185283B2 (ja) * 2006-12-29 2013-04-17 テイボテク・フアーマシユーチカルズ Ｈｉｖ阻害６−置換ピリミジン
PT2300013T (pt) 2008-05-21 2017-10-31 Ariad Pharma Inc Derivados de fósforo como inibidores de cinases
US9273077B2 (en) 2008-05-21 2016-03-01 Ariad Pharmaceuticals, Inc. Phosphorus derivatives as kinase inhibitors
TW201008933A (en) * 2008-08-29 2010-03-01 Hutchison Medipharma Entpr Ltd Pyrimidine compounds
KR101258331B1 (ko) 2008-09-11 2013-04-26 화이자 인코포레이티드 헤테로아릴 아미드 유도체 및 글루코키나제 활성화제로서의 그의 용도
AR074209A1 (es) 2008-11-24 2010-12-29 Boehringer Ingelheim Int Derivados de pirimidina utiles para el tratamiento del cancer
TWI491605B (zh) * 2008-11-24 2015-07-11 Boehringer Ingelheim Int 新穎化合物
MY151246A (en) 2009-03-11 2014-04-30 Pfizer Benzofuranyl derivatives
CA2816957A1 (en) 2010-11-07 2012-05-10 Targegen, Inc. Compositions and methods for treating myelofibrosis
WO2012135641A2 (en) 2011-03-30 2012-10-04 H. Lee Moffitt Cancer Center And Research Institute Aurora kinase inhibitors and methods of making and using thereof
US9834518B2 (en) 2011-05-04 2017-12-05 Ariad Pharmaceuticals, Inc. Compounds for inhibiting cell proliferation in EGFR-driven cancers
GB201119358D0 (en) 2011-11-10 2011-12-21 Lewi Paulus J Disubstituted triazine dimers for treatment and/or prevention of infectious diseases
GB201204756D0 (en) 2012-03-19 2012-05-02 Lewi Paulus J Triazines with suitable spacers for treatment and/or prevention of HIV infections
US20150166591A1 (en) 2012-05-05 2015-06-18 Ariad Pharmaceuticals, Inc. Methods and compositions for raf kinase mediated diseases
WO2014072419A1 (en) 2012-11-08 2014-05-15 Universiteit Antwerpen Novel anti-hiv compounds
US9611283B1 (en) 2013-04-10 2017-04-04 Ariad Pharmaceuticals, Inc. Methods for inhibiting cell proliferation in ALK-driven cancers
JP6740452B2 (ja) * 2016-07-26 2020-08-12 深▲セン▼市塔吉瑞生物医▲薬▼有限公司Ｓｈｅｎｚｈｅｎ ＴａｒｇｅｔＲｘ，Ｉｎｃ． プロテインチロシンキナーゼの活性を阻害するためのアミノピリミジン系化合物
CN106749203B (zh) * 2016-11-28 2020-04-10 洛阳聚慧医药科技有限公司 一种嘧啶类杂环化合物、嘧啶类杂环化合物盐以及制备方法和应用
EP3966207B1 (en) 2019-05-10 2023-11-01 Deciphera Pharmaceuticals, LLC Phenylaminopyrimidine amide autophagy inhibitors and methods of use thereof
MX2021013662A (es) 2019-05-10 2022-03-11 Deciphera Pharmaceuticals Llc Inhibidores de la autofagia de heteroarilaminopirimidina amida y metodos de uso de estos.
IL325201A (en) 2019-06-17 2026-02-01 Deciphera Pharmaceuticals Llc Aminopyrimidine amide autophagy inhibitors and methods of using them

Family Cites Families (22)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US3459731A (en) 1966-12-16 1969-08-05 Corn Products Co Cyclodextrin polyethers and their production
US5691364A (en) * 1995-03-10 1997-11-25 Berlex Laboratories, Inc. Benzamidine derivatives and their use as anti-coagulants
CN1198655C (zh) 1995-11-23 2005-04-27 詹森药业有限公司 通过熔体挤出法制备的环糊精固体混合物
NO311614B1 (no) * 1996-10-01 2001-12-17 Janssen Pharmaceutica Nv Substituerte diamino-1,3,5-triazinderivater
GB9705361D0 (en) 1997-03-14 1997-04-30 Celltech Therapeutics Ltd Chemical compounds
EP0945447A1 (en) 1998-03-27 1999-09-29 Janssen Pharmaceutica N.V. Trisubstituted 1,3,5-triazine derivatives for treatment of HIV infections
CZ299380B6 (cs) * 1998-03-27 2008-07-09 Janssen Pharmaceutica N. V. Pyrimidinová sloucenina, použití této slouceniny pro prípravu léciva, farmaceutický prostredek tutoslouceninu obsahující, zpusob prípravy tohoto prostredku a uvedené slouceniny a kombinace a produktuvedenou slouceninu obsahující
HRP20080359B1 (hr) * 1998-11-10 2016-01-01 Janssen Pharmaceutica N.V. PIRIMIDINI KOJI INHIBIRAJU REPLIKACIJU HIV-a
GB9828511D0 (en) * 1998-12-24 1999-02-17 Zeneca Ltd Chemical compounds
PL215901B1 (pl) 1999-04-15 2014-02-28 Bristol Myers Squibb Co Cykliczny inhibitor bialkowych kinaz tyrozynowych, jego zastosowanie oraz kompozycja farmaceutyczna zawierajaca taki zwiazek
GB9914258D0 (en) 1999-06-18 1999-08-18 Celltech Therapeutics Ltd Chemical compounds
CA2384188C (en) * 1999-09-24 2008-06-17 Janssen Pharmaceutica N.V. Antiviral compositions
WO2001025220A1 (en) * 1999-10-07 2001-04-12 Amgen Inc. Triazine kinase inhibitors
WO2001085700A2 (en) 2000-05-08 2001-11-15 Janssen Pharmaceutica N.V. Hiv replication inhibiting pyrimidines and triazines
AU2002216650A1 (en) * 2000-10-31 2002-05-15 Lynn Bonham Triazine derivatives as lpaat-b inhibitors and uses thereof
JO3429B1 (ar) 2001-08-13 2019-10-20 Janssen Pharmaceutica Nv مشتقات برميدينات مثبطة فيروس الايدز
TWI329105B (en) * 2002-02-01 2010-08-21 Rigel Pharmaceuticals Inc 2,4-pyrimidinediamine compounds and their uses
KR100875362B1 (ko) * 2002-02-05 2008-12-22 아스텔라스세이야쿠 가부시키가이샤 2,4,6-트리아미노-1,3,5-트리아진 유도체
AR039540A1 (es) * 2002-05-13 2005-02-23 Tibotec Pharm Ltd Compuestos microbicidas con contenido de pirimidina o triazina
AU2003244098A1 (en) * 2002-06-28 2004-01-19 Yamanouchi Pharmaceutical Co., Ltd. Diaminopyrimidinecarboxa mide derivative
ES2445208T3 (es) * 2002-07-29 2014-02-28 Rigel Pharmaceuticals, Inc. Compuestos de 2,4-pirimidindiamina para uso en métodos para tratar o prevenir enfermedades autoinmunitarias
CL2004000303A1 (es) * 2003-02-20 2005-04-08 Tibotec Pharm Ltd Compuestos derivados de pirimidinas y triazinas; proceso de preparacion; composicion farmaceutica; y su uso para inhibir la replicacion del vih.

Also Published As

Publication number Publication date
EP1603887A1 (en) 2005-12-14
JP2006518356A (ja) 2006-08-10
CN1751031A (zh) 2006-03-22
BRPI0407741B8 (pt) 2021-05-25
CN100572364C (zh) 2009-12-23
WO2004074262A1 (en) 2004-09-02
NO20054312D0 (no) 2005-09-19
NO20054311D0 (no) 2005-09-19
CN1751030A (zh) 2006-03-22
PL378136A1 (pl) 2006-03-06
TW200500346A (en) 2005-01-01
AP2005003373A0 (en) 2005-09-30
EP1597238B1 (en) 2007-05-09
WO2004074261A1 (en) 2004-09-02
BRPI0407741B1 (pt) 2018-05-29
ATE506353T1 (de) 2011-05-15
DE602004006383D1 (de) 2007-06-21
BRPI0407732A (pt) 2006-02-14
MXPA05008867A (es) 2005-10-05
EA200501327A1 (ru) 2006-02-24
DK1597238T3 (da) 2007-09-10
CA2516699A1 (en) 2004-09-02
HRP20050820A2 (en) 2006-11-30
AU2004213186B2 (en) 2009-10-01
AU2004213186A1 (en) 2004-09-02
IL169647A0 (en) 2007-07-04
PT1597238E (pt) 2007-08-08
IL169647A (en) 2013-05-30
NZ541601A (en) 2007-09-28
PL378064A1 (pl) 2006-02-20
NO20054312L (no) 2005-11-16
MY138308A (en) 2009-05-29
CL2004000303A1 (es) 2005-04-08
US20060194804A1 (en) 2006-08-31
JP2006518357A (ja) 2006-08-10
ES2287734T3 (es) 2007-12-16
AR044499A1 (es) 2005-09-14
DE602004006383T2 (de) 2008-01-10
CA2516589C (en) 2012-04-17
EA010423B1 (ru) 2008-08-29
AR044500A1 (es) 2005-09-14
EP1597238A1 (en) 2005-11-23
EP1603887B1 (en) 2011-04-20
PL227295B1 (pl) 2017-11-30
US7585870B2 (en) 2009-09-08
NZ542428A (en) 2007-11-30
JP4586014B2 (ja) 2010-11-24
ATE361915T1 (de) 2007-06-15
IL169596A (en) 2017-02-28
US20060142571A1 (en) 2006-06-29
IL169596A0 (en) 2007-07-04
CN1751031B (zh) 2010-07-21
CL2004000306A1 (es) 2005-04-08
HRP20050821A2 (en) 2006-11-30
CY1106788T1 (el) 2012-05-23
BRPI0407741A (pt) 2006-02-14
KR20050099994A (ko) 2005-10-17
CA2516589A1 (en) 2004-09-02
US7442705B2 (en) 2008-10-28
JP4586013B2 (ja) 2010-11-24
EA200501326A1 (ru) 2006-02-24
MXPA05008866A (es) 2005-10-05
TW200510339A (en) 2005-03-16
KR20050094896A (ko) 2005-09-28
AU2004213187B2 (en) 2009-11-05
AU2004213187A1 (en) 2004-09-02
CA2516699C (en) 2011-07-12
PL226954B1 (pl) 2017-10-31
DE602004032321D1 (de) 2011-06-01
EA011256B1 (ru) 2009-02-27

Similar Documents

Publication Publication Date Title
NO20054311L (no) HIV-repliksjonsinhiberende pyrimidiner og triaziner
NO20060001L (no) Nye P2X7-reseptorantagonister og deres anvendelse
NO20070224L (no) 2-karbamid-4-fenyltiazolderivater, fremstilling og terapeutisk anvendelse derav
NO20080675L (no) P38-Map kinaseinhibitorer og metoder for deres anvendelse
NO20085373L (no) P38 inhibitorer, deres fremstilling og anvendelse
NO20062726L (no) Nye pyridazin-3(2H)-on derivater
NO20081844L (no) Terapeutiske forbindelser
NO20084257L (no) Diketopiperazin og piperidin derivater som antivirale midler
NO20053470L (no) Triazolopyridaziner som proteinkinase-inhibitorer
MXPA03010207A (es) Nuevas 4-anilinoquinolin-3-carboxamidas.
NO20055837L (no) Immunsupprimerende forbindelser og sammensetninger
NO20063599L (no) Ytterligere heterosykliske forbindelser og deres anvendelse som metabotrofiske glutamatreseptorantagonister
NO20066055L (no) Pyridinderivater
NO20062677L (no) Benzyleteraminforbindelser anvendbare som CCR-5-antagonister
NO20054905L (no) 2-acylamino-4-fenyltiazolderivater, fremgangsmate for deres fremstilling og anvendelse av de samme som i terapeutika
NO20054726L (no) 2, 4-di(fenylamino)pyrimidiner anvendelige ved behandling av neoplastiske sykdommer, inflammasjons- og immunsystemforstyrrelser
WO2001085700A3 (en) Hiv replication inhibiting pyrimidines and triazines
NO20064062L (no) Prodroger av piperazin og substituerte piperidin antivirale midler
NO20071246L (no) Kinazolinonderivater og deres anvendelse som B-RAF-inhibitorer.
MY146669A (en) Pyrazole derivatives for treating hiv
NO20070681L (no) 2, 4, 6-Trisubstituterte pyrimidiner som fosfotidylinositol-(PI)-3-kinaseinhibitorer og disses anvendelse i behandling av kreft
NO20085087L (no) Nye heterocykliske forbindelser
SE0400284D0 (sv) Novel compounds
NO20050088L (no) Kationisk substituerte difenylazefidinoner, fremgangsmate for deres fremstilling, medikamenter inneholdende nevnte forbindelser og anvendelse derav
NO20082054L (no) Nye 2-fenylimidazo[4,5-b]pyridinderivater som inhibitorer av glykogensyntasekinase for behandling av demens og neurodegenerative forstyrrelser

Legal Events

Date Code Title Description
FC2A Withdrawal, rejection or dismissal of laid open patent application